NCT06813365View on ClinicalTrials.gov

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

PHASE1RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2027

Conditions
Nonsmall-cell Lung Cancer
Interventions
DRUG

DZD6008

Daily dose of DZD6008

Trial Locations (1)

100005

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY